Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Antibody-Mediated Rejection

Antibody-Mediated Rejection

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Antibody-Mediated Rejection

3 trials tracked for Antibody-Mediated Rejection: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 76 citations.

3Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 2
  1. Phase 3 The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation Completed · 76 cited
  2. Phase 2 Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation Completed
  3. Phase 2 Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Non-invasive biomarkers show promise for managing acute rejection in heart transplant recipients
Emergency Medicine Sys. Review
Non-invasive biomarkers show promise for managing acute rejection in heart transplant recipients New biomarkers show promise for monitoring heart transplant health
This narrative review evaluates non-invasive biomarkers, including donor-derived cell-free DNA and soluble proteins, for monitoring heart tr…
New non-invasive tests could help doctors detect heart transplant rejection earlier and reduce the need for invasive procedures.
Frontiers Sep 25, 2026
Narrative review examines metabolic syndrome and novel agents in kidney transplant recipients
Allergy & Immunology Sys. Review
Narrative review examines metabolic syndrome and novel agents in kidney transplant recipients Kidney transplant patients face high metabolic risks and rejection
This narrative review addresses antibody-mediated rejection and metabolic syndrome in kidney transplantation recipients. The authors note th…
About half of kidney transplant recipients develop metabolic problems within a year, while antibody-mediated rejection remains a major cause…
Frontiers May 21, 2026